FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics secures a new U.S. patent protecting its 3D fibroblast spheroid technology for accelerating healing in acute and chronic wounds.

Rhea-AI Summary

FibroBiologics (FBLG) received U.S. Patent No. 12,721,866 on September 1, 2026 for therapeutic use of fibroblasts in wound healing.

The patent covers topical administration of 3D spheroid fibroblasts and fibroblast-derived materials, including extracellular vesicles and exosomes, to treat and accelerate healing of acute and chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure wounds, burns, cuts, and abrasions. Preclinical models described in the patent showed wounds treated with fibroblast spheroids and fibroblast-derived materials healed significantly faster than controls in both diabetic and non-diabetic settings.

Positive

• New U.S. patent issued protecting topical 3D fibroblast spheroid wound-healing methods
• Preclinical data show treated wounds healed significantly faster than controls in diabetic and non-diabetic models

Negative

• None.

Market reaction after wound-healing patent issuance: FBLG -5.38%

-5.38% $1.84 2.7x vol

15m delay

-5.38% Vs previous close

-3.5% Trough in 0 min

$1.84 Last Price

$1.70 $1.99 Day Range

$12.28M Market Cap

2.7x Rel. Volume

Following this news, FBLG has declined 5.38%, reflecting a notable negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.84. Trading volume is elevated at 2.7x the average, suggesting increased selling activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

A 22.67% 24-hour gain followed FBLG’s September 1 degenerative-disc patent announcement, while four ...

Analysis

A 22.67% 24-hour gain followed FBLG’s September 1 degenerative-disc patent announcement, while four of five recent events aligned positively. The current wound-healing patent extends that record, but the active resale registration remains a financing consideration to monitor.

Key Figures

U.S. Patent Number: 12,721,866 Patent Issue Date: September 1, 2026 Patent Portfolio: 270+ patents +2 more

5 metrics

U.S. Patent Number 12,721,866 Issued by the USPTO

Patent Issue Date September 1, 2026 U.S. wound-healing patent

Patent Portfolio 270+ patents Issued and pending across clinical pathways

Patient Population Millions of patients Patients described as suffering from chronic and nonhealing wounds

Spheroid Dimension 3D Spheroid fibroblasts covered by the issued claims

Historical Context

5 past events · Latest: Sep 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Patent issuance	Positive	+22.7%	USPTO issued patent covering fibroblast conditioned media for degenerative disc disease.
Aug 27	Clinical supply release	Positive	+5.7%	Third CYWC628 drug-product batch shipped to Australia for the diabetic-foot-ulcer trial.
Aug 26	Nasdaq compliance	Positive	+0.7%	Nasdaq confirmed FBLG regained compliance with minimum bid-price requirements.
Aug 24	Board appointment	Neutral	-6.3%	Leigh Steinberg joined the board as a Class II director.
Aug 20	Patent acceptance	Positive	+8.0%	IP Australia accepted a patent application for cannabidiol adjuvant therapy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed four positive reactions to positive or operational announcements and one negative reaction to a management announcement.

Key Terms

extracellular vesicles, exosomes, microvesicles, apoptotic bodies

4 terms

extracellular vesicles medical

"including one or more of extracellular vesicles, exosomes, microvesicles"

Extracellular vesicles are tiny, cell-made particles—think microscopic bubbles—that carry proteins, genetic material and signals between cells. Investors care because these vesicles can be used as disease markers, drug-delivery vehicles, or therapeutic products; that creates opportunities and risks around clinical validation, manufacturing scale-up, intellectual property and regulatory approval that can materially affect the value of biotech and diagnostics companies.

exosomes medical

"including one or more of extracellular vesicles, exosomes, microvesicles"

Exosomes are tiny particles released by cells that carry proteins, genetic material, and other molecules from one cell to another. They act like biological messengers, helping cells communicate and coordinate their activities. For investors, understanding exosomes is important because they are being explored as potential tools for disease diagnosis and treatment, which could influence healthcare markets and innovation.

microvesicles medical

"exosomes, microvesicles, apoptotic bodies, and/or fragments of fibroblast cells"

Small, membrane-enclosed particles that cells shed into bodily fluids, carrying proteins, lipids and genetic material that can change how other cells behave. Like tiny courier packages or text messages sent between cells, microvesicles can reveal disease processes, act as targets or carriers for therapies, and serve as measurable biomarkers in tests, so they are important to investors tracking diagnostics, drug development and biologics platforms.

apoptotic bodies medical

"microvesicles, apoptotic bodies, and/or fragments of fibroblast cells"

Membrane-bound vesicles released when a cell undergoes programmed cell death (apoptosis); they contain bits of the cell’s interior such as proteins, DNA fragments and organelles and are packaged so they can be safely cleared by other cells. They matter to investors because their presence, composition or handling can be a measurable sign of how a therapy or disease affects cells, influence immune reactions, or serve as biomarkers or drug-delivery considerations in biotech development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds

HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers methods of treating and accelerating the healing of wounds by topically administering a therapeutically effective amount of a composition comprising fibroblasts and fibroblast-derived materials.

Nonhealing and difficult-to-heal wounds, including chronic wounds and diabetic ulcers, place a significant burden on the healthcare system and diminish quality of life for patients. Injury to the skin caused by disease, cuts, abrasions, bedsores, or burns can have a lasting impact on the physical, emotional, and psychological wellbeing of a patient, and factors such as age, health status, and underlying conditions, such as diabetes, can adversely impact the wound healing process. In preclinical studies described in the patent, wounds treated with fibroblast spheroids and fibroblast-derived materials healed significantly faster than controls, in both diabetic and non-diabetic models.

Key highlights of the issued claims include:

• A method of treating one or more type of wounds by topically administering a therapeutically effective composition comprising 3D spheroid fibroblasts or a fibroblast-derived material, including one or more of extracellular vesicles, exosomes, microvesicles, apoptotic bodies, and/or fragments of fibroblast cells.
  
  
• Treatment of chronic wounds such as diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure wounds, bedsores, burn wounds, as well as cuts, and abrasions.
  
  
• Methods of accelerating wound healing using a topically administered fibroblast spheroid composition.

"Wound care is one of the largest unmet needs in medicine, and this patent further solidifies our leadership position in fibroblast-based therapies," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "Our preclinical data showed that wounds treated with fibroblast spheroids healed significantly faster than controls, even in diabetic models where healing is notoriously difficult. We believe this technology has the potential to change the standard of care for millions of patients suffering from chronic and nonhealing wounds."

"Spheroids act as living reservoirs that implant on the wound surface, migrate, and proliferate, delivering regenerative signals directly where they are needed. Our studies demonstrated accelerated wound closure and reduced inflammation, which are critical factors in resolving chronic wounds," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials, including the potential to change the standard of care for chronic and nonhealing wounds. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-issuance-of-new-us-patent-for-the-therapeutic-use-of-fibroblasts-in-wound-healing-302868210.html

SOURCE FibroBiologics, Inc.

FAQ

What patent did FibroBiologics (FBLG) receive for fibroblast-based wound healing?

FibroBiologics received U.S. Patent No. 12,721,866, titled “Therapeutic Use of Fibroblasts for Use in Wound Healing.” The patent, issued on September 1, 2026, covers methods of treating and accelerating wound healing using topical compositions of fibroblasts and fibroblast-derived materials.

What does the new FibroBiologics (FBLG) patent cover for wound treatment?

The patent covers topically administering a therapeutically effective composition comprising 3D spheroid fibroblasts or fibroblast-derived materials such as extracellular vesicles, exosomes, microvesicles, apoptotic bodies, and fibroblast cell fragments to treat and accelerate healing of various wounds.

Which types of wounds are targeted by FibroBiologics’ new patent (FBLG)?

The patent includes methods to treat chronic and acute wounds, such as diabetic foot ulcers, venous leg ulcers, pressure wounds, bedsores, burn wounds, as well as cuts and abrasions, using topically administered fibroblast spheroid compositions or fibroblast-derived materials.

What preclinical results support FibroBiologics’ fibroblast spheroid wound therapy (FBLG)?

In preclinical studies described in the patent, wounds treated with fibroblast spheroids and fibroblast-derived materials healed significantly faster than control wounds in both diabetic and non-diabetic models, suggesting accelerated wound closure and reduced inflammation with this approach.

How does FibroBiologics describe the action of its fibroblast spheroids in wound healing?

FibroBiologics’ Chief Scientific Officer states that spheroids act as living reservoirs that implant on the wound surface, migrate, and proliferate, delivering regenerative signals directly where needed, with studies showing accelerated wound closure and reduced inflammation in chronic wound models.

What is FibroBiologics’ broader focus beyond this wound-healing patent (FBLG)?

FibroBiologics is a clinical-stage biotechnology company developing fibroblast-based treatments and potential cures for chronic diseases. It reports holding 270+ issued and pending patents across areas including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.